Lonza Announces Major Portfolio Transformation with Strategic Divestments – What Investors Need to Know
Lonza Announces Major Portfolio Transformation with Strategic Divestments – What Investors Need to Know
Summary of Key Developments
- Divestment of Capsules & Health Ingredients (CHI) Business: Lonza has signed an agreement to divest its CHI business to Lone Star Funds for an enterprise value of CHF 2.3 billion (USD 3 billion) at closing, expected in H2 2026.
- Financial Structure of the Deal: Lonza will receive upfront cash proceeds of CHF 1.7 billion (USD 2.2 billion) and will retain a 40% stake in CHI, with additional preferential participation in a future exit. The total undiscounted proceeds from the transaction are expected to be at or above CHF 3 billion (~USD 4 billion).
- Transformation to Pure-Play CDMO: With the divestment of CHI and additional non-core assets, Lonza solidifies its transformation into a pure-play Contract Development and Manufacturing Organization (CDMO), focusing on high-growth, high-margin pharmaceutical services.
- Proceeds Utilization and Capital Return: Lonza plans to allocate the upfront proceeds to organic growth opportunities aligned with its “One Lonza” strategy and bolt-on acquisitions. CHF 500 million will be returned to shareholders via a share buyback post-transaction.
- Additional Divestments: Agreements have also been signed to divest the Personalized Medicines business (Cocoon® Platform), MODA® software platform, and the small molecules micronization site in Monteggio, Switzerland.
- Financial Impact: Lonza expects to recognize a non-cash impairment of around CHF 1.3 billion related to the CHI assets in its FY2025 statements (to be published April 2026). This will be allocated to discontinued operations and will not impact CORE EBITDA of continuing operations.
- Credit Rating and Dividend Policy: The company remains committed to maintaining its investment-grade rating (S&P BBB+) and a progressive dividend policy, aiming to maintain or increase the dividend per share annually.
Strategic Rationale and Shareholder Implications
The divestment of the Capsules & Health Ingredients (CHI) business represents the final and most significant step in Lonza’s rapid transformation into a focused CDMO player. This move allows Lonza to concentrate resources on high-growth pharmaceutical contract services, which are expected to deliver low-teens constant exchange rate (CER) sales growth and expanding margins over time.
The deal structure is particularly noteworthy: by retaining a substantial minority stake (40%) and securing preferential participation in any future exit, Lonza positions itself to benefit from CHI’s anticipated return to growth after 2025, while also securing significant upfront liquidity for reinvestment.
Importantly for shareholders, CHF 500 million will be returned via a share buyback, following receipt of the proceeds. This capital return, combined with the expectation of accelerated organic and inorganic growth investments, has the potential to positively impact Lonza’s share price.
The company also continues to maintain a disciplined approach to capital allocation, with a clear framework for reviewing investment opportunities and returning surplus capital to shareholders. The ongoing commitment to a progressive dividend policy provides further reassurance of Lonza’s focus on shareholder value.
Other Notable Transactions and Portfolio Updates
- Personalized Medicines Business: The Cocoon® Platform will be divested to Octane Medical Group.
- MODA® Software Platform: To be sold to the parent company of STARLIMS Corporation.
- Monteggio Micronization Site: To be sold to Microsize and Schedio Group.
These divestments, alongside the CHI transaction, mean Lonza will now operate three complementary, integrated CDMO Business Platforms, all leveraging the company’s proprietary Lonza Engine® for competitive differentiation in complex and emerging pharmaceutical modalities.
Financial Outlook and Capital Allocation
Following the divestment, Lonza’s leverage is expected to fall materially below current target levels, reflecting the inflow of proceeds and a moderation of organic capital expenditures. The company will continue to review the potential for further investments or additional shareholder returns, depending on the capital requirements and market opportunities.
For FY2025, Lonza’s continuing CDMO business delivered sales of CHF 6.5 billion and a CORE EBITDA of CHF 2.1 billion, underscoring the scale and profitability of its remaining operations and providing a solid foundation for future growth.
Transaction Timeline and Next Steps
- Transaction closing for the CHI divestment is expected in the second half of 2026, subject to regulatory approvals and completion of legal separation.
- Lonza will account for the retained CHI stake as an investment in an associated company and will not have management control.
- Investor calls are scheduled for March 6 and March 9, 2026, with CEO Wolfgang Wienand and CFO Philippe Deecke presenting further details and addressing investor queries.
Potential Share Price Sensitivities
- The magnitude and certainty of upfront proceeds and future upside from the CHI divestment provide immediate and longer-term value for shareholders.
- Significant capital return via share buyback and ongoing progressive dividend policy are positives for share valuation.
- The expected non-cash impairment charge may impact reported net income for FY2025, but will not affect operational EBITDA.
- Clearer focus on the high-growth, high-margin CDMO segment could lead to a re-rating by investors seeking pure-play exposure.
- Execution risk remains around regulatory approvals, legal separation, and the future performance of the retained CHI stake.
About Lonza
Lonza is a leading global CDMO serving the healthcare industry, with approximately 20,000 employees worldwide. The company partners with pharma and biotech firms to bring innovative therapies to market, leveraging advanced science, technology, and manufacturing capabilities.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. All forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied. Lonza Group Ltd disclaims any intent or obligation to update forward-looking statements except as required by law. Please refer to official sources and consult with your financial advisor before making investment decisions.
View Lonza Historical chart here
